The Pharma Data

MAY 2, 2021

With eight marketed biosimilar medicines globally and 15+ molecules in pipeline, Sandoz is investing in future of biosimilars for patients and healthcare systems. Holzkirchen, May 3, 2021 – Sandoz, a Novartis division, today announced progress in the late-stage clinical development program for its proposed biosimilar aflibercept.

Clinical Development 40

Clinical Development Medicine Development Production 40

Delveinsight

FEBRUARY 5, 2021

According to the CDC, in 2018, tobacco companies spent over USD 9 Billion in just promoting and marketing their cigars and cigarettes in the US. Smoking Cessation: What are the drugs available in the market? Some of these approved products contain nicotine as an active ingredient, while others do not. Generics in the Market.

Marketing 52

Marketing FDA Approval Branding Production 52

pharmaphorum

OCTOBER 2, 2020

COMP360 is a crystalline formulation of psilocybin in phase 2b clinical development in patients who have not responded to standard therapy for depression. Compass has a patented synthetic version of psilocybin, the active ingredient in magic mushrooms, and raised around $127.5 million with its IPO shortly after the announcement.

Medicine 122

Medicine Life Science FDA Approval Development 122

The Pharma Data

AUGUST 31, 2021

In addition, as part of the label update, this indication has been revised to be for the treatment of patients with locally advanced or metastatic urothelial carcinoma (mUC) who are not eligible for any platinum-containing chemotherapy.

FDA Approval 52

FDA Approval Containment Clinical Development Trials 52

The Pharma Data

JANUARY 24, 2021

. (“Citius” or the “Company”) (Nasdaq: CTXR), a specialty pharmaceutical company focused on developing and commercializing critical care drug products, today announced that it has entered into securities purchase agreements with certain institutional and accredited investors to raise approximately $20.0

Marketing 40

Marketing Production Sales Containment 40

The Pharma Data

DECEMBER 30, 2020

Ensysce will use the funds to progress the clinical development of PF614, a first in class Trypsin Activated Abuse Protection (TAAP TM ) extended-release opioid prodrug, and its Multi-Pill Abuse Resistance (MPAR TM ) overdose protected counterpart, PF614-MPAR TM. “Our Global Emerging Markets (“GEM”) is a $3.4

Marketing 52

Marketing Production Drugs Containment 52

Pfizer

AUGUST 3, 2022

We innovate every day leveraging our global footprint to accelerate the development and delivery of groundbreaking medicines and the hope of cures. Learn more about our Rare Disease portfolio and how we empower patients, engage communities in our clinical development programs, and support programs that heighten disease awareness.

Development 101

Development Vaccine Vaccination Production 101

pharmaphorum

SEPTEMBER 3, 2020

The dynamic market, the patient journey and telemedicine. Prior to the pandemic, while repeat prescriptions could be made remotely, new and switch prescriptions (the dynamic market) necessitated a face-to-face visit by the patient to the healthcare professional.

Doctors 97

Doctors Doctor Production Marketing 97

pharmaphorum

APRIL 6, 2022

The ‘ gamification ’ of website design, app development, investment platforms, or just about any activity that exists on the internet, will contain examples of how this strategy maintains user engagement. Clinical development is no game.

Development 111

Development Clinical Development Production Trials 111

The Pharma Data

DECEMBER 10, 2020

executive vice president of research and development. “We We look forward to working closely with the FDA throughout the clinical development process to bring this potential new innovative treatment to patients as quickly as possible.”. For additional information, please visit www.lexpharma.com. Safe Harbor Statement.

Containment 52

Containment Clinical Development Development Protein 52

The Pharma Data

JANUARY 10, 2021

Based on its leading expertise in antibody, protein and peptide technologies, MorphoSys, together with its partners, has developed and contributed to the development of more than 100 product candidates, of which 27 are currently in clinical development.

Containment 52

Containment Clinical Development Antibody Development 52

Pharmaceutical Technology

NOVEMBER 25, 2022

In many cases, pharma companies select a contract development and manufacturing organisation (CDMO) to develop products versus doing the work themselves for reasons related to cost, convenience, and capacity. In one specific case, Cambrex developed a PDF containing two APIs in suspension in an 80/20 ratio.

Manufacturing 130

Manufacturing Production Pharma Companies Development 130

The Pharma Data

OCTOBER 26, 2020

(Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced the Company will release its third quarter 2020 financial results before the market opens on Thursday, November 5, 2020.

Clinical Trials 52

Clinical Trials Clinical Trials Containment Clinical Development 52

XTalks

DECEMBER 5, 2023

Augtyro, a tyrosine kinase inhibitor (TKI), is available as oral capsules, each containing 40 mg of repotrectinib. Other New Treatments for NSCLC on the Market The FDA has recently approved several other medications for various subsets of NSCLC patients.

Protein 115

Protein FDA Approval Medicine Trials 115

Pharmaceutical Technology

MARCH 2, 2023

Pembrolizumab is under clinical development by Merck and currently in Phase III for Bile Duct Cancer (Cholangiocarcinoma). According to GlobalData, Phase III drugs for Bile Duct Cancer (Cholangiocarcinoma) have a 53% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration.

FDA Approval 100

FDA Approval Containment Development Genomics 100

Pfizer

SEPTEMBER 28, 2022

This application for a variation of the marketing authorization (MA) to include the Omicron BA.4/BA.5-adapted 1-adapted bivalent vaccine, non clinical and manufacturing data from the companies’ 10-µg Omicron BA.4/BA.5-adapted COMIRNATY, which is based on BioNTech’s proprietary mRNA technology, was developed by both BioNTech and Pfizer.

Vaccination 101

Vaccination Vaccine Medicine Clinical Trials 101

Delveinsight

AUGUST 24, 2020

The launch of the Pipeline therapies, increasing EPI prevalence shall fuel the Exocrine pancreatic insufficiency market size estimated to be approximately USD 1,695.26 However, the main pharmacologic treatment and the mainstay in the Exocrine pancreatic insufficiency market is Pancreatic enzyme replacement therapy (PERT).

Marketing 52

Marketing Production Pharma Companies Containment 52

XTalks

APRIL 24, 2023

This is an increase from the EMA’s approval of two novel ATMPs with orphan designation in 2021 (although the marketing authorization for one of these ATMPs was withdrawn in the European Union in November 2021) and three novel ATMPs with orphan designation in 2020. How Can Study Protocols Be More Effective?

Gene Therapy 95

Gene Therapy Gene Trials Clinical Trials 95

The Pharma Data

JANUARY 13, 2021

Harpoon has four drug product candidates in clinical development for the treatment of solid and hematologic malignancies based on its proprietary TriTAC platform. In April 2020, Harpoon announced dosing of the first patient with HPN217 (BCMA TriTAC) in a Phase 1/2 clinical trial focused on relapsed/refractory multiple myeloma (RRMM).

Drugs 52

Drugs Clinical Trials Clinical Trials Containment 52

Pfizer

JULY 26, 2022

The Pfizer-BioNTech COVID-19 Vaccine, BNT162b2, which is based on BioNTech’s proprietary mRNA technology, was developed by both BioNTech and Pfizer. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines.

Vaccination 111

Vaccination Vaccine Protein Immune Response 111

Delveinsight

JULY 27, 2021

Afterwards on August 25, 2020 Shingrix received a proper commercial marketing authorization. This globalized COVID-19 vaccine supply chain and manufacturing network, incorporates 3 continents and will contain around 20 manufacturing facilities. In 2019 as the uptake increased, Shingrix sales double folded. billion people.

Vaccine 96

Vaccine Vaccination Trials Manufacturing 96

pharmaphorum

AUGUST 31, 2022

It is actually the control formulation used in clinical development of its original product MED2005, which contained glyceryl trinitrate as an active ingredient. However, “the USA remains the largest market opportunity globally for ED treatments,” said Futura’s chief executive, James Barder.

Drugs 52

Drugs FDA Approval Production Marketing 52

The Pharma Data

NOVEMBER 12, 2020

Five Prime plans to use the net proceeds of the offering, together with other available funds, to fund ongoing clinical development of bemarituzumab and FPT155, to advance FPA157 through preclinical and into clinical development, to advance its late-stage research programs and for working capital and general corporate purposes.

Containment 40

Containment Sales Clinical Development Development 40

Pfizer

JULY 8, 2022

In the European Union the conditional marketing authorization in this age group was granted by EMA in August 2021. COMIRNATY, which is based on BioNTech’s proprietary mRNA technology, was developed by both BioNTech and Pfizer. The information contained in this release is as of July 8, 2022. Pfizer Disclosure Notice.

FDA Approval 102

FDA Approval Vaccination Vaccine Clinical Trials 102

The Pharma Data

JANUARY 24, 2021

Sairiyo is a biotechnology company focused on repurposing and developing improved formulations of naturally derived compounds for serious, rare, and life-threatening diseases with the aim to obtain European Medicines Evaluation Agency and U.S. The global esophageal cancer drugs market is estimated to grow by USD $1.5

Drugs 52

Drugs Containment Development Clinical Development 52

Pfizer

JULY 19, 2022

The Pfizer-BioNTech COVID-19 Vaccine, which is based on BioNTech’s proprietary mRNA technology, was developed by both BioNTech and Pfizer. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines.

Vaccination 100

Vaccination Vaccine Medicine Clinical Trials 100

Pfizer

NOVEMBER 2, 2022

The vaccine candidate combines Pfizer’s quadrivalent modRNA-based influenza vaccine candidate, qIRV (22/23), which is currently in Phase 3 clinical development , and Pfizer and BioNTech’s authorized Omicron-adapted bivalent COVID-19 BNT162b2 (Original/Omicron BA.4/BA.5) COMIRNATY® (COVID-19 Vaccine, mRNA). INDICATION.

Vaccination 85

Vaccination Vaccine Clinical Trials Clinical Trials 85

Pfizer

FEBRUARY 16, 2023

Food and Drug Administration (FDA) and Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) in 2025, pending successful completion of the Phase 3 studies and subject to the agreement of these regulatory agencies to proposed modifications of the clinical trial plan.

Clinical Trials 76

Clinical Trials Clinical Trials Vaccine Vaccination 76

The Pharma Data

JANUARY 27, 2021

. A total of 15 patients have been recruited to date in the Phase I dose escalation part of the study, all of whom were late stage and have failed conventional treatments, including several lines of rituximab-containing therapies. ET ) to discuss the results and next steps in clinical development of BI-1206.

Antibody 52

Antibody Containment Development Trials 52

The Pharma Data

JANUARY 7, 2021

Cerecor intends to use the net proceeds of the offering for general corporate purposes and working capital, primarily to support the ongoing clinical development of key assets within its pipeline and for general and administrative expenses. The company is also developing two monoclonal antibodies, CERC-002, and CERC-007.

Clinical Development 52

Clinical Development Sales Development Containment 52

The Pharma Data

JANUARY 4, 2021

An experienced financial analyst and biotech executive, Dr. Farmer joins PureTech from BMO Capital Markets where he completed a 15-year career as a senior biotechnology equity analyst providing in-depth sector research for institutional investor clients. PureTech announced the appointment of George Farmer, Ph.D., as Chief Financial Officer.

Development 52

Development Production Marketing Medicine 52

The Pharma Data

DECEMBER 14, 2020

The IND covers the development of Rabeximod in Covid-19 and other indications, such as rheumatoid arthritis, and is a prerequisite for a future validation of the company’s five recent patent applications in the US market. “Filing an IND with the FDA is an important step in the clinical development of Rabeximod.

Clinical Trials 40

Clinical Trials Clinical Trials Clinical Development Drugs 40

Pfizer

DECEMBER 8, 2022

The vaccine candidate is based on BioNTech’s proprietary mRNA platform technology and contains mRNA strands encoding the wild-type spike protein of SARS-CoV-2 and the spike protein of the Omicron sublineages BA.4/BA.5, The information contained in this release is as of December 9, 2022. COMIRNATY® (COVID-19 Vaccine, mRNA). INDICATION.

Vaccination 81

Vaccination Vaccine Clinical Trials Clinical Trials 81

Pfizer

JULY 8, 2022

COMIRNATY, which is based on BioNTech’s proprietary mRNA technology, was developed by both BioNTech and Pfizer. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Pfizer Disclosure Notice.

Vaccination 81

Vaccination Vaccine Clinical Trials Clinical Trials 81

The Pharma Data

JUNE 28, 2021

Food and Drug Administration (FDA) and a marketing authorization application (MAA) to the European Medicines Agency (EMA) seeking approval of the novel combination of the cancer treatments copanlisib and rituximab. and China for marginal zone lymphoma (MZL) based on clinical data of MZL patients enrolled in the CHRONOS-1 study.

Trials 52

Trials Containment Branding Development 52

The Pharma Data

OCTOBER 18, 2020

Developed and marketed by Janssen, Tremfya (R) is the first approved fully human monoclonal antibody that selectively binds to the p19 subunit of IL-23 and inhibits its interaction with the IL-23 receptor. Tremfya (R) is a registered trademark of Janssen Biotech, Inc.

Clinical Development 40

Clinical Development Antibody Development Production 40

The Pharma Data

JANUARY 13, 2021

Complete approval for these indications is contingent upon results from ongoing randomized, controlled confirmatory clinical trials. Our 5,000+ employees in China, the United States, Australia, Europe, and elsewhere are committed to expediting the development of a diverse pipeline of novel therapeutics. Forward-Looking Statements.

Production 52

Production Trials Antibody Clinical Trials 52